Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease

doi:10.4253/wjge.125564

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(3)

(0)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Endoscopy

ISSN

1948-5190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Endosc. Oct 16, 2026; 18(10): 125564
Published online Oct 16, 2026. doi: 10.4253/wjge.125564

Table 2 Cox regression of factors associated with upadacitinib discontinuation and discontinuation or intensification in patients with ulcerative colitis (n = 42)

n = 42	Univariate			Multivariate
Discontinuation (17 events)	HR	95%CI	P value	HR	95%CI	P value
Smoking	9.40	1.51-58.6	0.016	11.37	1.64-78.95	0.014
CRP (mg/L)	1.08	1.01-1.16	0.023	1.09	1.01-1.18	0.029
Discontinuation or intensification (27 events)	HR	95%CI	P value	HR	95%CI	P value
Female	0.21	0.05-0.94	0.041	0.20	0.05-0.91	0.037
Extensive colitis (E3)	2.95	0.92-9.42	0.068	3.30	1.03-10.58	0.045

CI: Confidence interval; CRP: C-reactive protein; HR: Hazard ratio.

Full Size Table

Citation: Kitsou V, Kokkotis G, Avatziadis P, Ioannou A, Michopoulos S, Zampeli E, Bamias G. Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease. World J Gastrointest Endosc 2026; 18(10): 125564
URL: https://www.wjgnet.com/1948-5190/full/v18/i10/125564.htm
DOI: https://dx.doi.org/10.4253/wjge.125564

Kitsou V, Kokkotis G, Avatziadis P, Ioannou A, Michopoulos S, Zampeli E, Bamias G. Real-world clinical outcomes, prognostic factors, and safety profile of upadacitinib in patients with inflammatory bowel disease. World J Gastrointest Endosc 2026; 18(10): 125564 [DOI: 10.4253/wjge.125564]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.